Company news

Teva Pharmaceutical Industries Limited news in 2025

Teva Pharmaceutical Industries Limited's news releases, calls and decks from 2025, newest first.

View company

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

December 24, 2025

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

December 19, 2025

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

December 12, 2025

Teva Releases Q4 2025 Aide Memoire

December 12, 2025

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

December 9, 2025

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

December 1, 2025

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

November 25, 2025

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

November 21, 2025

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

November 19, 2025

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

November 7, 2025

Teva Canada Welcomes RAMQ Reimbursement Update Supporting Access to ADHD Treatments

November 6, 2025

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

November 5, 2025

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

November 3, 2025

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

October 31, 2025

Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar

October 21, 2025

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

October 20, 2025

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

October 10, 2025

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

September 25, 2025

Teva Releases Q3 2025 Aide Memoire

September 25, 2025

Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®

September 23, 2025

Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed

September 22, 2025

Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®

September 22, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

September 19, 2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

September 19, 2025

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

September 17, 2025

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

September 16, 2025

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

September 9, 2025

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

September 2, 2025

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

August 28, 2025

Teva Debuts Autumn Winter 2025 Collection Inspired By "For Playground Earth"

August 19, 2025

Teva® and Sean Wotherspoon Reimagine Archival Icons, Bridging Street Style and Outdoor Adventure

August 14, 2025

Vantage Drilling International Ltd. Announces Completion of the Sale of the Tungsten Explorer

August 11, 2025

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

August 6, 2025

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

July 30, 2025

EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships

July 21, 2025

Teva Releases Q2 2025 Aide Memoire

June 26, 2025

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

June 25, 2025

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

June 23, 2025

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 16, 2025

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

June 3, 2025

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

June 3, 2025

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30, 2025

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

May 29, 2025

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 29, 2025

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27, 2025

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27, 2025

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

May 27, 2025

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

May 22, 2025

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

May 20, 2025

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

May 20, 2025

Older news releases →

Calls in 2025

Decks in 2025